Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of (a) UK Research and Innovation and (b) National Institute for Health and Care Research funding for biomedical research into (i) myalgic encephalomyelitis and (ii) chronic fatigue syndrome.

The Government funds research through the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC).

We have assessed the myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), research portfolio funded through the NIHR and the MRC and acknowledge that this is an under-funded area. The level of funding awarded is directly related to the number and quality of applications received and we have historically received a small number of applications for funding in this area. Between 2019/20 and 2023/24, the NIHR committed approximately £3.7 million to research projects and programmes on ME/CFS. In the same period, the MRC committed approximately £2.9 million to research into ME/CFS. We welcome funding applications for research into ME/CFS. These applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money, and scientific quality.

We aim to publish the final delivery plan for ME/CFS shortly. The plan will focus on boosting research, improving attitudes and education, and bettering the lives of people with this debilitating condition. Following the publication of the final delivery plan, we will monitor the progress across all actions in the delivery plan, with project management arrangements in place to ensure timely implementation and periodical reports to stakeholders as appropriate.

Together with the MRC, we are actively exploring next steps for research in ME/CFS, and we will outline in the delivery plan further research actions and the additional support we will offer to the research community to increase the volume and quality of applications. This includes a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical inventions for post-acute infection syndromes and associated conditions, including ME/CFS. This funding opportunity is a key component of our response to the need for further research-based evidence related to the diagnosis, management, and treatment of post-acute infection conditions, including ME/CFS. We are also planning an NIHR and MRC hosted showcase event for post-acute infection conditions, including ME/CFS and long COVID, research later this year to stimulate further research in this field.